AZN - AstraZeneca PLC
38.75 0.00 (0.00%)
After hours: 4:15PM EDT
| Previous Close | 38.80 |
| Open | 38.78 |
| Bid | 38.72 x 800 |
| Ask | 38.73 x 2200 |
| Day's Range | 38.56 - 38.90 |
| 52 Week Range | 34.38 - 43.30 |
| Volume | 4,248,858 |
| Avg. Volume | 5,427,251 |
| Market Cap | 99.362B |
| Beta (3Y Monthly) | 0.56 |
| PE Ratio (TTM) | 45.59 |
| EPS (TTM) | 0.85 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.40 (3.46%) |
| Ex-Dividend Date | 2019-02-28 |
| 1y Target Est | 46.10 |
- Zacks•4 days ago
AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why
AVEO Pharmaceuticals (AVEO) suffers a major hindrance as it defers its NDA filing for Fotivda in the United States.
- Zacks•5 days ago
Top Ranked Income Stocks to Buy for April 17th
Top Ranked Income Stocks to Buy for April 17th
- Zacks•7 days ago
Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
- Market Realist•7 days ago
AstraZeneca’s Oncology Portfolio: Growth Trends in 2019
Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Oncology portfolio growth trends During AstraZeneca’s (AZN) fourth-quarter earnings investor presentation, the company highlighted the potential of its oncology drug,
- Reuters•7 days ago
London's FTSE 100 tugged down by miners; IWG lifts midcaps
(Reuters) - Britain's main index lost ground on Monday as miners and oil majors fell, more than offsetting gains in bank stocks. The FTSE 100 was 0.2 percent lower, lagging its European and Asian counterparts, ...
- Market Realist•10 days ago
PFE or AZN: Comparing Their Earnings Growth in 2019
Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Earnings guidance On its fourth-quarter earnings conference call, Pfizer (PFE) said that it expected its 2019 adjusted diluted EPS to be $2.82–$2.92, which doesn’t
- Market Realist•10 days ago
What Are Analysts Recommending for PFE and AZN?
Pfizer or AstraZeneca: Which Is a Better Pick in April?Stock price movementsOn April 11, Pfizer (PFE) closed at $42.27, 1.08% lower than its previous closing price, 22.99% higher than its 52-week low of $34.37, and 9.04% below its 52-week high of
- Zacks•10 days ago
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
- Zacks•10 days ago
Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall
The index traversed a lackluster trading week as investors looked toward first-quarter earnings numbers for direction.
- Investopedia•12 days ago
Here's what to expect from the stock market next month
History favors a sustained rally after the strongest first quarter in a decade, but challenges remain as growth slows in the U.S., China and Europe.
- InvestorPlace•12 days ago
Is AstraZeneca Stock Worth Buying Before Earnings?
Last year's extreme sentiment fears have abated and now the equity markets are back near all-time highs. This includes stocks like AstraZeneca (NYSE:AZN) as it set a new high late last month. From that standpoint, this is not an obvious entry point into AZN stock, but whether you should buy the stock also depends on a few other factors.Source: Shutterstock Those who want to own AZN shares for the long term can afford to ignore short-term downside risk. But for most other investors who prefer to start an ownership position into a stock in the green should be slightly more surgical than just jumping in at any time.AZN stock is on a tear up 11% in 12 months. But the company will report earnings on April 26 and those events are wild. So this makes buying the stock now a short-term binary bet. Reactions to earnings scorecards are usually more to do with expectations than the actual value of a stock.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBefore you label me a hater, my caution for AstraZeneca stock here is not a dis against the company itself or its prospects. I am merely concerned with buying into a stock that is not likely to fall soon thereafter. Looking back on its prior reactions to earnings, they are split. * 10 Dow Jones Stocks Holding the Blue Chip Index Back Last quarter, the stock spiked drastically on the results, which left a giant open gap in the chart. Although this does not happen all of the time, Wall Street usually likes to fill these gaps.Since the spike to all-time highs, AZN stock has been drifting lower and testing recent support. If it loses $40 per share, it risks triggering a bearish pattern that would close the gap below. Although this is not a forecast, it is a scenario that could unfold here and investors need to be aware of it.The good news is that $39 per share is a mid-term pivot level and those tend to lend support on the way down. These are zones that the bulls and bears find interesting, so they will fight it out and create price congestion. How to Approach AZN Stock NowSo far my reservation to owning the shares immediately has been technically based. Fundamentally, AZN stock is not cheap as it sells at a price-to-earnings ratio of 47. This is more than three times as expensive as Bristol-Myers Squibb (NYSE:BMY) and twice as expensive as Apple (NASDAQ:AAPL) … to draw absolute and relative comparisons, respectively.Moreover, healthcare and biotech stocks are back in the sights of the political rifles. This is the only current bipartisan consensus topic. Both Democrats and Republicans want to vilify and persecute the drug companies. The rhetoric of both sides involves bringing legislation that would bring down the price of medicine and change the current Health Care Act. * 7 Vulnerable Stocks to Watch On Brexit News and Trade Wars These are nervous times on Wall Street. The S&P 500 has been on an extended run since the December crash and that makes investors nervous. Almost everyone I hear in the media suggests that traders are ready to sell at the first sign of trouble. So the prevailing idea is that we've come too far too fast. For some reason, they didn't say that on the way down, when last year we fell even faster and farther.But for now, we have to respect the collective and be cautious. This is not an obvious time to load up on new positions of AZN stock, even if it means I would miss out on a few upside dollars if it rips. And for those who already own AstraZeneca stock, it's not an alarm to sell out of the position. Furthermore, the options markets offer many ways I can temporarily defend my shares by selling covered calls or buying puts. Doing both would be a dollar neutral strategy.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Medical Marijuana Stocks to Cure Your Portfolio * 8 Best Stocks to Buy for an April Rally * Top 20 Stocks to Buy for 20-Somethings! Compare Brokers The post Is AstraZeneca Stock Worth Buying Before Earnings? appeared first on InvestorPlace.
- Zacks•12 days ago
Alkermes Reports Positive Data From Schizophrenia Study
Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.
- Zacks•12 days ago
J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store?
J&J's (JNJ) sales growth in first-quarter 2019 is expected to be hurt by generic/biosimilar headwinds in the Pharma unit.
- Zacks•12 days ago
AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer
AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.
- Zacks•13 days ago
PhaseBio Stock Up on Breakthrough Therapy Status for PB2452
FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.
- Zacks•13 days ago
Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457
Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.
- Zacks•14 days ago
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
- Simply Wall St.•15 days ago
Is AstraZeneca PLC's (LON:AZN) Balance Sheet A Threat To Its Future?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! There are a number of reasons that attract investors towards large-cap companies such as AstraZeneca PLC (LON:AZN), with a ma...
- Zacks•17 days ago
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
- Zacks•17 days ago
Will Ironwood Suffer From Dependence on Linzess' Progress?
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.
- Zacks•17 days ago
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU
Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
- Zacks•17 days ago
Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck
The expanded partnership will help Myriad Genetics (MYGN) boost top-line contributions in the near term.
- Zacks•18 days ago
Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up
Inovio's (INO) investigational HPV therapy, INO-3106, achieves the clinical efficacy for treating patients with recurrent respiratory papillomatosis, an HPV-associated disease. Shares up.
